Desensitization to imatinib in patients with leukemia

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Imatinib mesylate, a tyrosine kinase inhibitor, treats chronic myeloid leukemia and hypereosinophilic syndrome.
• Adverse cutaneous reactions, including rash, are common side effects of imatinib therapy.
• Understanding these reactions is crucial for patient management and treatment adherence.

Observation:

• A study evaluated oral desensitization using incremental imatinib mesylate dosages in ten leukemia patients with prior rash.
• The desensitization procedure was conducted over 4 hours in an outpatient setting.
• Patient outcomes were monitored for up to 3 years post-procedure.

Findings:

• No anaphylaxis or serious adverse events occurred during desensitization.
• Four patients experienced no rash recurrence; four had manageable recurrent rashes.
• Two patients developed recurrent rashes and could not continue imatinib therapy.

Implications:

• Oral desensitization may enable some leukemia patients to tolerate imatinib, facilitating continued life-prolonging treatment.
• The findings suggest that imatinib-induced rashes might stem from hypersensitivity rather than direct pharmacologic effects.
• This protocol offers a potential strategy for managing imatinib-associated cutaneous adverse events.